MINIREVIEWS

2419 Current status of radical laparoscopy for treating hepatocellular carcinoma with portal hypertension
Shen ZF, Liang X

ORIGINAL ARTICLE

Retrospective Cohort Study

2433 Impact of type 2 diabetes on adenoma detection in screening colonoscopies performed in disparate populations

2446 Early colonoscopy and urgent contrast enhanced computed tomography for colonic diverticular bleeding reduces risk of rebleeding
Ochi M, Kamoshida T, Hamano Y, Ohkawara A, Ohkawara H, Kakinoki N, Yamaguchi Y, Hirai S, Yanaka A

Retrospective Study

2458 Relationship between mismatch repair protein, RAS, BRAF, PIK3CA gene expression and clinicopathological characteristics in elderly colorectal cancer patients
Fan JZ, Wang GF, Cheng XB, Dong ZH, Chen X, Deng YJ, Song X

Clinical Trials Study

2469 Possible effect of blonanserin on gambling disorder: A clinical study protocol and a case report
Shiina A, Hasegawa T, Iyo M

Observational Study

2478 Parents' experience of caring for children with type 1 diabetes in mainland China: A qualitative study
Tong HJ, Qiu F, Fan L

2487 Differences in dietary habits of people with vs without irritable bowel syndrome and their association with symptom and psychological status: A pilot study
Meng Q, Qin G, Yao SK, Fan GH, Dong F, Tan C

SCIENTOMETRICS

2503 Prognostic nomograms for predicting overall survival and cause-specific survival of signet ring cell carcinoma in colorectal cancer patients
Kou FR, Zhang YZ, Xu WR
## CASE REPORT

**2519**  
Cerebellar artery infarction with sudden hearing loss and vertigo as initial symptoms: A case report  
*Wang XL, Sun M, Wang XP*

**2524**  
Three-dimensional-printed custom-made patellar endoprosthesis for recurrent giant cell tumor of the patella: A case report and review of the literature  

**2533**  
Gastrointestinal-type chemotherapy prolongs survival in an atypical primary ovarian mucinous carcinoma: A case report  

**2542**  
Neoadjuvant chemoradiotherapy followed by laparoscopic distal gastrectomy in advanced gastric cancer: A case report and review of literature  
*Liu ZN, Wang YK, Li ZY*

**2555**  
Extravascular spinal epidural plasmocytoma associated with multiple myeloma: Two case reports  
*Cui JF, Sun LL, Liu H, Gao CP*

**2562**  
Endoscopic diagnosis of early-stage primary esophageal small cell carcinoma: Report of two cases  
*Er LM, Ding Y, Sun XF, Ma WQ, Yuan L, Zheng XL, An NN, Wu ML*

**2569**  
Nemaline myopathy with dilated cardiomyopathy and severe heart failure: A case report  
*Wang Q, Hu F*

**2576**  
Immunoglobulin D-λ/λ biclonal multiple myeloma: A case report  
*He QL, Meng SS, Yang JN, Wang HC, Li YM, Li YX, Lin XH*

**2584**  
Point-of-care ultrasound for the early diagnosis of emphysematous pyelonephritis: A case report and literature review  

**2595**  
Minimally invasive treatment of forearm double fracture in adult using Acumed forearm intramedullary nail: A case report  
*Liu JC, Huang BZ, Ding J, Mu XJ, Li YL, Piao CD*

**2602**  
*Klebsiella pneumoniae* infection secondary to spontaneous renal rupture that presents only as fever: A case report  
*Zhang CG, Duan M, Zhang XY, Wang Y, Wu S, Feng LL, Song LL, Chen XY*

**2611**  
Eltrombopag-related renal vein thromboembolism in a patient with immune thrombocytopenia: A case report  
*Wu C, Zhou XM, Liu XD*

**2619**  
*Cryptococcus* infection with asymptomatic diffuse pulmonary disease in an immunocompetent patient: A case report  
*Li Y, Fang L, Chang FQ, Xu FZ, Zhang YB*
## Contents

**Thrice Monthly Volume 9 Number 11 April 16, 2021**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2627</td>
<td>Triple administration of osimertinib followed by chemotherapy for advanced lung adenocarcinoma: A case report</td>
<td>Hu XY, Fei YC, Zhou WC, Zhu JM, Lv DL</td>
</tr>
<tr>
<td>2634</td>
<td>Anesthetic management of a child with double outlet right ventricle and severe polycythemia: A case report</td>
<td>Tan LC, Zhang WY, Zuo YD, Chen HY, Jiang CL</td>
</tr>
<tr>
<td>2641</td>
<td>Combined immune checkpoint inhibitors of CTLA4 and PD-1 for hepatic melanoma of unknown primary origin: A case report</td>
<td>Cheng AC, Lin YJ, Chiu SH, Shih YL</td>
</tr>
<tr>
<td>2655</td>
<td>Surgical therapy for hemangioma of the azygos vein arch under thoracoscopy: A case report</td>
<td>Wang ZX, Yang LL, Xu ZN, Lv PY, Wang Y</td>
</tr>
<tr>
<td>2662</td>
<td>Calcium pyrophosphate deposition disease of the temporomandibular joint invading the middle cranial fossa: Two case reports</td>
<td>Tang T, Han FG</td>
</tr>
<tr>
<td>2671</td>
<td>Rare histological subtype of invasive micropapillary carcinoma in the ampulla of Vater: A case report</td>
<td>Noguchi H, Higashi M, Idichi T, Kurahara H, Mataki Y, Tasaki I, Kitazono I, Ohtsuka T, Tanimoto A</td>
</tr>
<tr>
<td>2688</td>
<td>Melatonin for an obese child with MC4R gene variant showing epilepsy and disordered sleep: A case report</td>
<td>Ge WR, Wan L, Yang G</td>
</tr>
</tbody>
</table>
ABOUT COVER
Editorial Board Member of World Journal of Clinical Cases, Hong-Tao Xu, MD, PhD, Chief Physician, Professor, Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences of China Medical University, Shenyang 110001, Liaoning Province, China. xuht@cmu.edu.cn

AIMS AND SCOPE
The primary aim of World Journal of Clinical Cases (WJCC, World J Clin Cases) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING
The WJCC is now indexed in Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, PubMed, and PubMed Central. The 2020 Edition of Journal Citation Reports® cites the 2019 impact factor (IF) for WJCC as 1.013; IF without journal self cites: 0.991; Ranking: 120 among 165 journals in medicine, general and internal; and Quartile category: Q3. The WJCC’s CiteScore for 2019 is 0.3 and Scopus CiteScore rank 2019: General Medicine is 394/529.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Jia-Hui Li; Production Department Director: Yu-Jie Ma; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL
World Journal of Clinical Cases

ISSN
ISSN 2307-8960 (online)

LAUNCH DATE
April 16, 2013

FREQUENCY
Thrice Monthly

EDITORS-IN-CHIEF
Dennis A Bloomfield, Sandro Vento, Bao-Gan Peng

EDITORIAL BOARD MEMBERS
https://www.wjgnet.com/2307-8960/editorialboard.htm

PUBLICATION DATE
April 16, 2021

COPYRIGHT
© 2021 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/GerInfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com
Neoadjuvant chemoradiotherapy followed by laparoscopic distal gastrectomy in advanced gastric cancer: A case report and review of literature

Zi-Ning Liu, Yin-Kui Wang, Zi-Yu Li

Abstract

BACKGROUND
The laparoscopic technique has been widely applied for early gastric cancer, with the advantages of minimal invasion and quick recovery. However, there is no report about the safety and oncological outcome of laparoscopic gastrectomy with D2 lymph node dissection for patients after neoadjuvant chemoradiotherapy.

CASE SUMMARY
A 60-year-old man was diagnosed with advanced distal gastric cancer, T4aN1M0 stage III. The neoadjuvant chemoradiotherapy was performed based on the regimen of gross tumor volume 50Gy/25f and clinical target volume 45Gy/25f, as well as concurrent S-1 60 mg Bid. Then laparoscopic distal gastrectomy with D2 lymph node dissection was undertaken successfully for him after achieving partial response evaluated by radiological examination. The patient recovered smoothly without moderate or severe postoperative complications. The postoperative pathological stage was ypT3N0M0 with American Joint Committee on Cancer tumor regression grade 1. He was still in good condition after 5 years of follow-up.

CONCLUSION
Neoadjuvant chemoradiotherapy followed by laparoscopic technique could be applicable and may achieve satisfactory oncological outcomes. Our finding requires further validation by cohort studies.

Key Words: Gastric cancer; Neoadjuvant chemoradiotherapy; Laparoscopic; Distal gastrectomy; S-1; Case report
A 60-year-old man presented with abdominal distension and weight loss of over 10 kg for approximately 6-mo duration.

History of present illness
He was an otherwise healthy man with no remarkable medical history.

History of past illness
There was no obvious abnormality in any past illness.

Personal and family history
There was no special history and personal history. The patient had no known family history of cancer.

Physical examination
Physical examinations revealed a thin, emaciated male with normal vital signs. The

Core Tip: The radicalness for locally advanced gastric cancer depends on the completed R0 resection. Although perioperative treatment strategies have been widely used for patients to reinforce the treatment effect, the use of neoadjuvant chemoradiation is controversial, let alone whether the patients can benefit from minimally invasive surgery. We presented the first case treated by laparoscopic distal gastrectomy in advanced gastric cancer: A case report and review of literature. World J Clin Cases 2021; 9(11): 2542-2554
URL: https://www.wjgnet.com/2307-8960/full/v9/i11/2542.htm
DOI: https://dx.doi.org/10.12998/wjcc.v9.i11.2542

INTRODUCTION
Since the first case of laparoscopic distal gastrectomy was reported by Kitano in 1994[8], the laparoscopic technique has been widely applied in early gastric cancer, with the advantages of minimal invasion and quick recovery[9-11]. Laparoscopic gastrectomy is the preferred option for early gastric cancer. The promising outcome from such surgery has promoted the application of laparoscopy in advanced gastric cancer. Although it is not known whether laparoscopic gastrectomy was suitable for locally advanced gastric cancer, the safety and feasibility of laparoscopic gastrectomy have been explored in several clinical trials[12-14]. Inspiring results have been achieved by these studies, proving that laparoscopic gastrectomy for locally advanced gastric cancer is not inferior to that of open surgery. Although surgery is the only curative option for gastric cancer, the mortality of patients after radical surgery remains high because of a significant number of local regional or systemic recurrences[15]. Chemoradiotherapy has been recommended as a supplement to radical surgery by the National Comprehensive Cancer Network[16]. Postoperative therapy administration is restricted in some patients due to surgical complications because the recovery time may exceed the prescribed time period for treatment[17]. However, perioperative treatment modality can avoid the shortcomings. Neoadjuvant chemoradiotherapy (NACRT) has the advantages of avoiding unnecessary surgery by shrinking the tumor size and facilitating a high rate of R0 resection, with acceptable rates of acute and late toxicities[18-20]. To the best of our knowledge, this is the first report to date regarding the safety and short-term oncological outcome of NACRT followed by laparoscopic D2 gastrectomy.

CASE PRESENTATION
Chief complaints
A 60-year-old man presented with abdominal distension and weight loss of over 10 kg for approximately 6-mo duration.

History of present illness
He was an otherwise healthy man with no remarkable medical history.

History of past illness
There was no obvious abnormality in any past illness.

Personal and family history
There was no special history and personal history. The patient had no known family history of cancer.

Physical examination
Physical examinations revealed a thin, emaciated male with normal vital signs. The
abdomen was tender, and there was no palpable mass. Superficial lymphadenopathy was not detected.

**Laboratory examinations**

Routine blood test revealed small cell hypochromic anemia: The hemoglobin was 85 g/L; the mean corpuscular volume was 65 fL; the mean corpuscular hemoglobin was 18.60 pg; the mean corpuscular hemoglobin concentration was 286 g/L. His white blood cell (6.24 × 10^9/L) and platelet (333 × 10^9/L) were within the normal range. Neutrophil-to-lymphocyte ratio was 2.25. The blood biochemistry was normal except for albumin, which was 30.0g/L. All tumor markers in gastrointestinal cancer were within the normal range: Carcinoma embryonic antigen was 3.44 ng/mL, cancer antigen 19-9 was 12.69 U/mL, cancer antigen 72-4 was 3.78 U/mL, and cancer antigen 242 was 10.76 U/mL.

**Imaging examinations**

An endoscopy was undertaken and revealed an ulcerative lesion adjacent to the gastric antrum, with a dike-like bulge around the edge. Pylorus was invaded by the lesion, resulting in an incomplete obstruction. Enhanced abdominal computed tomography (CT) indicated that the wall of the antrum was thickened with significant enhancement, with a maximum thickness of 21 mm. The surface of the serosa was fuzzy; however, the border near the pancreas remained clear. Multiple enlarged lymph nodes were found in the lesser gastric curvature; the diameter of the largest one was 7mm. No distant metastasis was detected from the pelvis or chest CT.

**HISTOPATHOLOGICAL EXAMINATIONS**

The pathology obtained from the endoscopic biopsy confirmed a moderate to poor differentiated adenocarcinoma, with a Lauren type of intestine.

**FINAL DIAGNOSIS**

The patient was diagnosed as having a gastric antrum carcinoma, Borrmann type III, with lymph nodes metastases. The clinical stage was confirmed as being cT4aN1M0 stage III.

**TREATMENT**

**NACRT and evaluation**

The patient and his family had a very strong desire for radicalness of surgery. However, because of the wide infiltration of the primary foci with suspicion of lymph nodes metastasis, which were majorly localized on the lesser curvature, a direct surgery may not be capable of radical cure. A tumor downstaging by chemoradiation was strongly recommended for the preparation of surgical radicalness. Moreover, the patient was 60-years-old. Despite his stable physical status before cancer diagnosis, with 172 cm height and 45 kg weight, his body mass index was only 15.2 kg/m² with nutritional deficiency anemia at the moment. Even if the patient received a completed D2 lymphadenectomy with R0 resection, his nutritional status required a long period of recovery. The chance that he could benefit from, or be able to receive, the adjuvant treatment was bleak, as adjuvant chemotherapy is often assumed to have little benefit for delayed initiation. With the concerns above, a preoperative concurrent radio-chemo therapy was designed by the multidisciplinary team.

The NACRT was given at a total dose of gross tumor volume 50 Gy and clinical target volume 45 Gy, in 25 fractions, five times a week, with concurrent S-1 60 mg twice daily. The NACRT was well tolerated with no severe adverse events according to the Common Terminology Criteria for Adverse Events v5.0[16]. The most serious problems among the mild-to-moderate adverse events was the grade 2 white blood cell decrease (white blood cells count 2.92 × 10^9/L) 3 wk after radiotherapy (RT) completion. The white blood cell count went back to normal (8.69 × 10^9/L) after oral leucocyte increasing drugs treatment (Diyu Shengbai tablets) for 3 wk. For the incomplete obstruction, enteral nutrition was recommended for the patient.
Gastrointestinal fiberscope before chemoradiotherapy showed an ulcerative lesion located surrounding the gastric antrum with ulceration causing stenosis. A-D: Tumor surface identified from different angles and distances.

nutrition status of the patient gradually improved during the NACRT and waiting period. With a 15 kg increase in weight, his albumin rose to 41.4 g/L, and the hemoglobin returned to 101 g/L. His neutrophil-to-lymphocyte ratio, on the other hand, dropped to 1.87 before surgery.

An enhanced abdominal CT was performed to evaluate the response of NACRT at the time of completion and 6 wk after NACRT (Figure 3). The tumor thickness showed sustained shrinkage from 21-12 mm to 12-10 mm during the NACRT period. With shrinkage rate by 52%, a partial response was considered by the multidisciplinary team[17]. Endoscopic ultrasound was performed using a radial scanning ultrasound endoscope to evaluate the response of NACRT at the same time (Figure 4), which indicated an ulcerative lesion adjacent to the gastric antrum with pyloric stenosis. The lesion was reflected as a hypoechoic signal under the endoscopic ultrasound, invading the entire layer, partly to the serosa with the maximum thickness 1.09 cm. A hypoechoic nodule beside the antrum, measuring approximately 2.05 cm × 1.3 cm in size, was also detected. Therefore, an uT4aN1M0 tumor after NACRT was considered and restaged.

Surgery and postoperative recovery
Open distal gastrectomy with D2 lymph node dissection was planned for the patient. However, the patient was very eager to receive only minimally invasive surgery, and thus refused open surgery. The patient received laparoscopy-assisted distal gastrectomy with D2 lymph node dissection and Billroth II anastomosis successfully 4 wk after the last evaluation. The entire surgical procedure was recorded on video. The operation lasted for 240 min. The blood loss was 100 mL. The first flatus time was 3 d after the operation. Upper gastrointestinal radiography was performed 7 d after the operation, indicating that gastric peristalsis was good with no anastomosis leakage. The patient was allowed to intake a liquid diet and was then discharged on day 12 without grade II or more Clavien-Dindo complications[18].

OUTCOME AND FOLLOW-UP
Postoperative pathological evaluation was completed 7 d after surgery. Small groups of cancer cells were detected outside of the muscularis propria, accompanied by the
Figure 2 Enhanced abdominal computerized tomography indicated that the wall of the antrum was thickened with significant enhancement. The surface of serosa was fuzzy, but the border near the pancreas was still clear (yellow arrowheads). Multiple enlarged lymph nodes were found in the lesser gastric curvature (orange arrowheads). A-B: Transverse views of the primary lesion in different layers; C: Coronal view of the primary lesion; D: Sagittal view of the primary lesion.

formation of extracellular mucus pools, which were surrounded by fibrosis and chronic inflammatory cells (Figure 5). The necrosis rate was > 90% (residual tumor/tumor bed < 10%). Thus, the patient was evaluated as tumor regression grade 1 based on American Joint Committee on Cancer/College of Pathology criteria and as tumor regression grade 2 for Japanese Gastric Cancer Association system, both belonging to a subtotal regression. No vascular embolus or perineuronal invasion was detected. No metastases were found in lymph nodes (0/31). Fibrosis was detected in some lymph nodes, which was considered as change post NACRT. No cancer cell was detected in the gastric stump or duodenal stump. Therefore, the pathological stage was ypT3N0M0.

One month after the operation, the patient returned to the clinic for a follow-up. The enhanced abdominal CT and all the laboratory tests showed that the patient was generally in good condition. Adjuvant chemotherapy was conducted with three cycles of S-1 plus oxaliplatin. Five years after the surgery, the patient was still in good condition, with no recurrence or metastasis.

DISCUSSION

The results of ARTIST and ARTIST-2 have put chemoradiotherapy (CRT) into an uncertain situation in patients undergoing D2 lymphadenectomy\(^\text{[19,20]}\). In ARTIST, although the postoperative chemotherapy plus CRT revealed a superior benefit in disease-free survival (DFS) compared to chemotherapy alone in patients with positive lymph node metastasis, the survival benefit was not retained in all patients\(^\text{[20]}\). In the subsequent ARTIST-II trial interim result, no difference in DFS between S-1 and oxaliplatin (SOX) and SOX plus CRT was found \((P = 0.667)\)\(^\text{[19]}\). However, as gastric adenocarcinoma is theoretically radio-sensitive, the futility of CRT may be credited to more ways than one: Does the minimal peritoneal metastasis already exist before treatment; is the delineation of gastric lymph node stations under the same treating protocol? On the other hand, rather than being a role of supplementary or salvage after surgery, NACRT brings more than what postoperative RT/CRT can offer. Not only do patients have better performance status and are often more tolerant to
Figure 3 Enhanced abdominal computerized tomography performed before, immediately after, and 6 wk after neoadjuvant chemoradiotherapy to evaluate the response to neoadjuvant chemoradiotherapy. Imaging after neoadjuvant chemoradiotherapy (NACRT) imaging revealed maximum thickness change from 21 mm to 12 mm (shrinking 42.9%) with lymph nodes (diameter 7 mm) in the great curve shrinking so obviously that they could not be clearly detected in the computed tomography, but the surface of the serosa was still fuzzy. The computed tomography 6 wk after neoadjuvant chemotherapy indicated a change from 12 mm to 10 mm (shrinking 16.7%) with no obviously enlarged lymph nodes around the stomach, retroperitoneal area, or pelvis. A-C: Transverse views of the lesion’s change from pre-NACRT to post-NACRT; D-E: Coronal views of the lesion’s change from pre-NACRT to post-NACRT.

radiation predated to surgery, but it could minimize the primary site, enhance the R0 resection rate (especially for those with borderline resectable tumor), reduce the extent of surgery (conserving stomach), benefit form minimal invasion, etc.

The depiction of NACRT is restricted by the scant number of clinical trials with high levels of evidence. As we reviewed the phase II/III studies of NACRT (not for esophagogastric junction or esophagus) on gastric cancer following curative gastrectomy from the past 20 years through a search of the PubMed, MEDLINE and EMBASE (language was limited to English, Table 1 and 2)[21-34], to date only Skoropad et al[32] reported a complete phase III trial result with no significant findings in 10-year overall survival (NACRT + Surgery vs Surgery, 32% vs 18%). However, neither the dose nor the technique in target delineation met the current standard. Patients in their study received RT rather than CRT modalities that are commonly accepted today. While the rest of the phase III trials are worth watching (Table 2), many phase II trials can shed light on the patterns of NACRT. The higher rate of pCR (mean pCR rate 16.4% in initially resected cases) can be found in most of them (Table 1), when compared with neoadjuvant chemotherapy, usually no more than 10%[35].

It is now been recognized that mature laparoscopic technique did not greatly influence patients survival as well as postoperative complications[36,37]. Also, the number of retrieved lymph nodes in the laparoscopic procedure was not inferior to open surgery. Zhao et al[38] reported a retrospective study of 659 patients who were treated by laparoscopic or open gastrectomy and found that the average number of lymph node dissections in the laparoscopic gastrectomy and open gastrectomy group were 33.2 and 32.8, respectively, with no significant difference. The average time for the laparoscopic gastrectomy and open gastrectomy procedures did not differ significantly (211 ± 56 min vs 204 ± 41 min); however, bleeding during the operation in the laparoscopic group was significantly less than that in the open group (128 ± 85 mL
Table 1 Phase II published studies of neoadjuvant/preoperative radiation/chemoradiation following curative gastrectomy in gastric cancer (with or without esophagogastric junction)

<table>
<thead>
<tr>
<th>Author</th>
<th>Year of published</th>
<th>N (RT + Surgery/RT)</th>
<th>Eligibility</th>
<th>Preoperative treatment arms</th>
<th>Surgery</th>
<th>Response rate</th>
<th>Survival</th>
<th>Adverse outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roth et al[21]</td>
<td>2003</td>
<td>18/18</td>
<td>Stomach, LAGC</td>
<td>CF × 2 + RT (3 titers)</td>
<td>D2</td>
<td>6% pCR, 50% ORR</td>
<td>2-yr OS 71%, 3-yr OS 59%</td>
<td>No TRM; no postoperative death; 17% minimal peritoneal carcinomatosis; 44% grade 3-4 AE</td>
</tr>
<tr>
<td>Skoropad et al[22]</td>
<td>2003</td>
<td>67/91</td>
<td>Stomach (43% distal), cM0</td>
<td>45 Gy/25 fractions + metronidazole</td>
<td>D1</td>
<td>NA</td>
<td>5-yr OS 46%, 10-yr OS 36%, MST 46 mo</td>
<td>No TRM; 26% metastasis/inoperable; 6% postoperative death; 4% grade 4 AE</td>
</tr>
<tr>
<td>Ajani et al[23]</td>
<td>2004</td>
<td>29/33</td>
<td>Stomach/EGJ (24% distal), cT2-3NxM0 or cT1N1M0</td>
<td>45 Gy/25 fractions + 5-Fu</td>
<td>D2</td>
<td>30% pCR, 55% ORR</td>
<td>2-yr OS 54%, MST 34 mo</td>
<td>3% TRM; 3% postoperative death; 12% metastasis/inoperable; no grade 4 AE</td>
</tr>
<tr>
<td>Ajani et al[24]</td>
<td>2006</td>
<td>36/43</td>
<td>Stomach/EGJ (23% antrum), cT2-3NxM0 or cT1N1M0</td>
<td>CF × 2 → 45Gy/25 fractions + 5-Fu</td>
<td>D2</td>
<td>recommended</td>
<td>1-yr OS 72%, MST 23 mo</td>
<td>No TRM; no postoperative death; 17% progression; 5% grade 3 AE; 58% site failure</td>
</tr>
<tr>
<td>Wydmanski et al[25]</td>
<td>2007</td>
<td>32/40</td>
<td>Stomach, LAGC (31% middle/distal)</td>
<td>45 Gy/25 fractions + 5-Fu</td>
<td>D2</td>
<td>recommended</td>
<td>1-yr OS 75%, 2-yr OS 63%, MST not reach</td>
<td>5% TRM; no postoperative death; 12.5% metastasis/inoperable; no grade 4 AE</td>
</tr>
<tr>
<td>Rivera et al[26]</td>
<td>2011</td>
<td>8/13</td>
<td>Stomach/EGJ (41% distal), initially unresectable cM0</td>
<td>IC × 2 → 45 Gy/25 fractions + IC</td>
<td>D1 and beyond</td>
<td>No pCR, 8% PR</td>
<td>2-yr OS 27%, MST 10.5 mo (in 17 patients)</td>
<td>15% TRM; 12.5% postoperative death; 23% metastasis/inoperable; 46% grade 3-4 neutropenia</td>
</tr>
<tr>
<td>Pera et al[27]</td>
<td>2012</td>
<td>31/41</td>
<td>Stomach/EGJ/Esophagus (29% stomach), locally advanced (M0)</td>
<td>Oxaliplatin/cisplatin/5-FU + 45 Gy/25 fractions</td>
<td>D2</td>
<td>recommended</td>
<td>2-yr OS 58%, MST 28 mo</td>
<td>2% TRM; 13% postoperative death; 24% progression/inoperable; 14% grade 3-4 neutropenia</td>
</tr>
<tr>
<td>Michel et al[28]</td>
<td>2014</td>
<td>31/42</td>
<td>Stomach/EGJ (45% lower), cT &gt; 2 or cN &gt; 1 (M0)</td>
<td>FOLFIRI × 4 → 50 Gy/25 fractions + 5-Fu</td>
<td>D2</td>
<td>7% pCR</td>
<td>2-yr OS 27%, MST 26 mo</td>
<td>No TRM; 17% postoperative death; 6% metastasis; 41% grade 3-4 AE</td>
</tr>
<tr>
<td>Trip et al[29]</td>
<td>2014</td>
<td>24/25</td>
<td>Stomach, cTNM IB-IV (M0)</td>
<td>45 Gy/25 fractions + TC</td>
<td>D1+, D2</td>
<td>16% pCR, 77% ORR</td>
<td>MST 15 mo</td>
<td>No TRM; 4% postoperative death; 4% progression; no grade 4 AE</td>
</tr>
<tr>
<td>Liu et al[30]</td>
<td>2018</td>
<td>33/36</td>
<td>Stomach/EGJ, cTNM III (53% lower)</td>
<td>SOX × 1 → 45 Gy/25 fractions + S-1 → SOX×1</td>
<td>D2</td>
<td>recommended</td>
<td>1-yr OS 92%, 2-yr OS 56%, MST 30 mo</td>
<td>No TRM, no postoperative death; 3% metastasis; no grade 4 AE</td>
</tr>
<tr>
<td>Kim et al[31]</td>
<td>2019</td>
<td>31/39</td>
<td>Stomach/EGJ (33% antrum), high-risk</td>
<td>TP5 × 2 → 45 Gy/25 fractions + CS</td>
<td>D2</td>
<td>10% pCR, 33% ORR</td>
<td>3-yr OS 76%, MST not reach</td>
<td>No TRM; no postoperative death; 15% metastasis/inoperable; no grade 4 AE during CRT</td>
</tr>
</tbody>
</table>

AE: Adverse events; CF: Cisplatin/5-Fu; CRT: Chemoradiotherapy; CS: Cisplatin/S-1; DCF: Docetaxel/Cisplatin/5-Fu; EGJ: Esophagogastric junction; FOLFIRI: Fluorouracil/Leucovorin/Irinotecan; Gy: Grey; IC: Irinotecan/Cisplatin; LAGC: Locally advanced gastric cancer; MST: Median survival time; NA:
Not available; ORR: Objective response rate; OS: Overall survival; pCR, Pathological complete response; PR: Partial response; RT: Radiotherapy; SOX: S-1/Oxaliplatin; TC: Paclitaxel/Carboplatin; TPS: Docetaxel/Cisplatin/S-1; TRM: Treatment-related mortality.

\[ vs 301 \pm 156 \text{ mL, } P < 0.001. \] Similar results were confirmed by Pugliese et al\(^\text{[39]}\) and Hwang et al\(^\text{[40]}\). Additionally, although with limited cases, several studies revealed laparoscopic and open gastrectomy had comparable long-term and short-term outcomes\(^\text{[41-43]}\).

Our previous experience has proved neoadjuvant chemotherapy does not increase the complications of radical gastrectomy\(^\text{[44]}\). In this case, the number of lymph node dissection was 31 and the blood loss was 100 mL without complications, which may indicate that the laparoscopic technique is applicable to patients with advanced gastric cancer after NACRT. However, in this case, the severe fibrosis around the stomach make the surgery more difficult and delicate, resulting in a relatively longer operation time (240 min) in the patient treated by NACRT compared to those who were not. Yet with the amplification effect of laparoscopy, laparoscopic gastrectomy was safe and feasible for advanced gastric patients who were treated by an experienced department.

Although the patient in our department recovered smoothly with no postoperative complications, it remains debatable whether NACRT followed by laparoscopic gastrectomy increases postoperative complications. The most frequent complications for gastric cancer patients after NACRT have been reported as nonspecific surgical complications\(^\text{[45]}\).

**CONCLUSION**

NACRT followed by laparoscopic distal gastrectomy with D2 lymph node dissection was safe and achieved satisfactory oncological outcomes for the present patient. However, well-designed prospective trials are still required to prove whether laparoscopic gastrectomy can be recommended as an initial treatment for advanced distal gastric cancer after NACRT.
# Phase III published and ongoing studies of neoadjuvant/preoperative radiation/chemoradiation following curative gastrectomy in gastric cancer (with or without esophagogastric junction)

<table>
<thead>
<tr>
<th>Ref.</th>
<th>Trial (accrual period)</th>
<th>No pts</th>
<th>Eligibility</th>
<th>Treatment/Design</th>
<th>Surgery</th>
<th>Response rate</th>
<th>Survival</th>
<th>Adverse outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skoropad et al[32]</td>
<td>(1974-1978)</td>
<td>102</td>
<td>Stomach/EGJ, cM0</td>
<td>20 Gy / 5 fractions → S vs S</td>
<td>D1 and beyond</td>
<td>NA</td>
<td>5-yr OS 30% vs 39%, NS; 10-yr OS 52% vs 18%, NS</td>
<td>Complications 57% vs 49%, NS; postoperative death 9.8% vs 11.8%, NS</td>
</tr>
<tr>
<td>Leong et al[34]</td>
<td>TOPGEAR (2009-2014)</td>
<td>75</td>
<td>Stomach/EGJ, cTNM IB-IIIC</td>
<td>ECF×2 → 45 Gy / 25 fractions + 5-Fu → S → ECF × 3 vs ECF × 3 → S → ECF × 3</td>
<td>D2, D1+</td>
<td>NA</td>
<td>In progress</td>
<td>No/noncurative surgery, 15% vs 10%, NS; Grade 3-4 AE 52% vs 50%, NS; surgical complications 22% vs 22% NS</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/study/NCT01815833">https://clinicaltrials.gov/ct2/show/study/NCT01815833</a></td>
<td>Neo-CRAG (2013-)</td>
<td>620</td>
<td>LAGC, cT3N2/N3M0, cT4aN+M0, cT4bNanyM0</td>
<td>45 Gy / 25 fractions → XELOX × 3 → S → XELOX × 3 vs XELOX × 3 → S → XELOX × 3</td>
<td>D2</td>
<td>In progress</td>
<td>In progress</td>
<td>In progress</td>
</tr>
<tr>
<td>Liu et al[34]</td>
<td>PREACT (2016-)</td>
<td>682</td>
<td>Stomach/EGJ, LAGC</td>
<td>SOX × 1 → 45 Gy / 25 fractions + S-1 → SOX × 1 → S → SOX × 3 vs SOX × 3 → S → SOX × 3</td>
<td>D2</td>
<td>In progress</td>
<td>In progress</td>
<td>In progress</td>
</tr>
</tbody>
</table>

AE: Adverse events; ECF: Epirubicin/cisplatin/5-Fu; EGJ: Esophagogastric junction; Gy: Grey; LAGC: Locally advanced gastric cancer; NA: Not available; NS: Not significant; OS: Overall survival; S: Surgery; SOX: S-1/Oxaliplatin; XELOX: Capecitabine/Oxaliplatin.
Figure 4 Endoscopic ultrasound was also applied to evaluate the response to neoadjuvant chemoradiotherapy, indicating that the ulcerative lesion location surrounded the gastric antrum with pyloric stenosis. A: Endoscopic view of the posttreatment lesion; B-D: Endoscopic ultrasound image of post-treatment lesion.

Figure 5 Postoperative pathological evaluation showed that the pathological stage after neoadjuvant chemoradiotherapy was T3N0M0, with necrosis rate > 90%. A: Hematoxylin and eosin stain; B: Human epidermal growth factor receptor 2 immunohistochemical stain highlights carcinoma cells (stained brown).

REFERENCES


Liu ZN et al. A case of LDG after NACRT

18855063 DOI: 10.1007/s00464-008-0140-5


